Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)

被引：0
|
作者：
Pujade-Lauraine, Eric
Weber, Beatrice E.
Ray-Coquard, Isabelle
Vergote, Ignace
Selle, Frederic
Del Campo, Jose Maria
Sufliarsky, Jozef
Tschoepe, Inga
Chesa, Pilar Garin
Nazabadioko, Serge
Pilz, Korinna
Joly, Florence
机构：
[1] Hop Hotel Dieu, AP HP, Unite Oncol Med, F-75181 Paris, France
[2] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium
[6] Hop Tenon, F-75970 Paris, France
[7] Vall dHebron Inst Oncol, Barcelona, Spain
[8] Natl Canc Inst, Bratislava, Slovakia
[9] Boehringer Ingelheim GmbH & Co KG, Reims, France
[10] Boehringer Ingelheim GmbH & Co KG, Vienna, Austria
[11] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[12] Ctr Francois Baclesse, F-14021 Caen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer
    Bryan Oronsky
    Carolyn M. Ray
    Alexander I. Spira
    Jane B. Trepel
    Corey A. Carter
    Hope M. Cottrill
    Medical Oncology, 2017, 34
  • [42] Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer
    Niu, J.
    Kundranda, M. N.
    Markman, M.
    Farley, J.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2017, 38 (01) : 40 - 44
  • [43] Platinum-resistant ovarian cancer: Prematurely stopped phase Ⅱ Austrian AGO chemotherapy studies
    Edgar Petru
    Birgit Volgger
    Gerhard Bogner
    Lukas Angleitner-Boubenizek
    Martina Deibl
    Christian Schauer
    Alexander Reinthaller
    Gerhard Wolfram
    Alain Gustave Zeimet
    Christian Marth
    World Journal of Obstetrics and Gynecology, 2012, (03) : 35 - 39
  • [44] Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: Results of a phase II trial
    Sood, AK
    Lush, R
    Geisler, JP
    Shahin, MS
    Sanders, L
    Sullivan, D
    Buller, RE
    Sorosky, JI
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6080 - 6085
  • [45] AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace B.
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David T.
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer
    Hinchcliff, Emily M.
    Knisely, Anne
    Adjei, Naomi
    Fellman, Bryan
    Yuan, Ying
    Patel, Ami
    Xu, Cai
    Westin, Shannon N.
    Sood, Anil K.
    Soliman, Pamela T.
    Shafer, Aaron
    Fleming, Nicole D.
    Gershenson, David M.
    Vikram, Raghunandan
    Bathala, Tharakeswara
    Vining, David
    Ganeshan, Dhakshina M.
    Lu, Karen H.
    Sun, Charlotte C.
    Meyer, Larissa A.
    Jazaeri, Amir A.
    CANCER, 2024, 130 (07) : 1061 - 1071
  • [47] Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Roque, Dana
    Siegel, Eric
    Buza, Natalia
    Bellone, Stefania
    Silasi, Dan-Arin
    Huang, Gloria
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter
    Rao, Gautam
    Reader, Jocelyn
    Hui, Pei
    Tymon-Rosario, Joan
    Harold, Justin
    Mauricio, Dennis
    Zeybek, Burak
    Menderes, Gulden
    Altwerger, Gary
    Ratner, Elena
    Santin, Alessandro
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S58 - S58
  • [48] Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Dana M. Roque
    Eric R. Siegel
    Natalia Buza
    Stefania Bellone
    Dan-Arin Silasi
    Gloria S. Huang
    Vaagn Andikyan
    Mitchell Clark
    Masoud Azodi
    Peter E. Schwartz
    Gautam G. Rao
    Jocelyn C. Reader
    Pei Hui
    Joan R. Tymon-Rosario
    Justin Harold
    Dennis Mauricio
    Burak Zeybek
    Gulden Menderes
    Gary Altwerger
    Elena Ratner
    Alessandro D. Santin
    British Journal of Cancer, 2024, 130 : 1073 - 1073
  • [49] Gemcitabine (G) and epirubicin (E) combination, in platinum-resistant or refractory advanced ovarian cancer (PROC) patients: Results of a multicentric phase II trial
    Murgia, V.
    Caffo, O.
    Sorio, R.
    Griso, C.
    Scalone, S.
    Ferro, A.
    Caldara, A.
    Arisi, E.
    Lo Re, G.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] PHASE I/II TRIAL OF GLIF FOR TAXANE/PLATINUM-RESISTANT ENDOMETRIAL CANCER
    Nakagawa, S.
    Ueda, Y.
    Matsuzaki, S.
    Takata, T.
    Kobayashi, E.
    Sawada, K.
    Tomimatsu, T.
    Yoshino, K.
    Kimura, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 299 - 299
12345